Pan Tumor Rollover Study
ConditionCancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Eligibility criteria
Qualifiers
Signed Written Informed Consent.
Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.
Disqualifiers
Participant is not eligible for study treatment per the Parent Study eligibility criteria.
Participants not receiving clinical benefit as assessed by the Investigator.
Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
Other protocol-defined Inclusion/Exclusion Criteria apply
Trial design
Treatments tested in this trial
- Nivolumab
- Ipilimumab
- Cabozantinib
- Trametinib
- Relatlimab
- Nivolumab + Relatlimab
- Capecitabine
- Bevacizumab
- Temozolomide
- Rucaparib
- Daratumumab
- Regorafinib
- Leucovorin
- Fluorouracil
- Oxaliplatin
- Enzalutamide
- Sunitinib
- Pemetrexed
- Pembrolizumab
Treatment groups
1,500 Participants
are divided into 32 treatment groups32
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Bristol-Myers Squibb
Lead sponsor
Exelixis
Collaborator
Novartis
Collaborator
Clovis Oncology, Inc.
Collaborator
Janssen Pharmaceuticals
Collaborator
Source ClinicalTrials.gov